Bo Angelin

List of Publications by Year
in descending order

220	16,052	16791 66	21843 118
papers	citations	h-index	g-index

222	222	222	15111
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Obese mother offspring have hepatic lipidic modulation that contributes to sex-dependent metabolic adaptation later in life. Communications Biology, 2021, 4, 14.	2.0	10
2	Founder effects facilitate the use of a genotypingâ€based approach to molecular diagnosis in Swedish patients with familial hypercholesterolaemia. Journal of Internal Medicine, 2021, 290, 404-415.	2.7	3
3	Selective estrogen receptor (ER)Î² activation provokes a redistribution of fat mass and modifies hepatic triglyceride composition in obese male mice. Molecular and Cellular Endocrinology, 2020, 502, 110672.	1.6	20
4	Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism. Journal of Lipid Research, 2020, 61, 480-491.	2.0	65
5	A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human Beings. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 149-170.	2.3	30
6	Regulation of bile acid metabolism in biliary atresia: reduction of FGF19 by Kasai portoenterostomy and possible relation to early outcome. Journal of Internal Medicine, 2020, 287, 534-545.	2.7	12
7	How to handle hypertriglyceridaemia in acute pancreatitis â€“ Still a vote for conservatives?. Journal of Internal Medicine, 2019, 286, 723-725.	2.7	3
8	Unique case of cerebrotendinous xanthomatosis revisited: All the mutations responsible for this disease are present in the <scp>CYP</scp>27A1 gene. Journal of Internal Medicine, 2018, 283, 604-606.	2.7	5
9	Asynchronous rhythms of circulating conjugated and unconjugated bile acids in the modulation of human metabolism. Journal of Internal Medicine, 2018, 284, 546-559.	2.7	26
10	An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers. Gastroenterology, 2018, 155, 1012-1016.	0.6	44
11	Mental distress in treatment seeking young adults (18â€“25 years) with severe obesity compared with population controls of different body mass index levels: cohort study. Clinical Obesity, 2017, 7, 1-10.	1.1	16
12	Metabolic Syndrome: One Speckled Stone Kills a Flock of Birds?. Trends in Molecular Medicine, 2017, 23, 97-99.	3.5	0
13	Treatment with the natural <scp>FXR</scp> agonist chenodeoxycholic acid reduces clearance of plasma <scp>LDL</scp> whilst decreasing circulating <scp>PCSK</scp>9, lipoprotein(a) and apolipoprotein Câ€<scp>III</scp>. Journal of Internal Medicine, 2017, 281, 575-585.	2.7	52
14	Can <scp>LDL</scp> cholesterol be too low? Possible risks of extremely low levels. Journal of Internal Medicine, 2017, 281, 534-553.	2.7	69
15	Cholestyramine treatment of healthy humans rapidly induces transient hypertriglyceridemia when treatment is initiated. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E167-E174.	1.8	24
16	Highâ€density lipoproteinâ€associated sphingosineâ€1â€phosphate activity in heterozygous familial hypercholesterolaemia. European Journal of Clinical Investigation, 2017, 47, 38-43.	1.7	3
17	Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitusâ€”Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 787-791.	1.1	33
18	Arginase inhibition improves endothelial function in patients with familial hypercholesterolaemia irrespective of their cholesterol levels. Journal of Internal Medicine, 2016, 279, 477-484.	2.7	39

#	Article	IF	Citations
19	Circulating Hepcidin-25 Is Reduced by Endogenous Estrogen in Humans. PLoS ONE, 2016, 11, e0148802.	1.1	56
20	Who is the Treatment-Seeking Young Adult with Severe Obesity: A Comprehensive Characterization with Emphasis on Mental Health. PLoS ONE, 2015, 10, e0145273.	1.1	24
21	Influence of dietary sugar on cholesterol and bile acid metabolism inÂthe rat: Marked reduction of hepatic Abcg5/8 expression following sucrose ingestion. Biochemical and Biophysical Research Communications, 2015, 461, 592-597.	1.0	6
22	Letter to the Editor: Potential Role for FGF21 as a Mediator of Thyroid Hormone Effects on Metabolic Regulation. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L130-L131.	1.8	1
23	Reductions in serum levels of <scp>LDL</scp> cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liverâ€selective thyroid hormone receptor agonist eprotirome. Journal of Internal Medicine, 2015, 277, 331-342.	2.7	43
24	Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. Journal of Lipid Research, 2015, 56, 463-469.	2.0	70
25	Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients. Journal of Lipid Research, 2015, 56, 1633-1639.	2.0	4
26	Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. Journal of Lipid Research, 2014, 55, 2408-2415.	2.0	71
27	Influence of growth hormone on circulating fibroblast growth factor 21 levels in humans. Journal of Internal Medicine, 2013, 274, 227-232.	2.7	19
28	Fifty years of lipoprotein(a) â€“ the Magical Mystery Tour continues. Journal of Internal Medicine, 2013, 273, 3-5.	2.7	4
29	Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metabolism, 2013, 17, 225-235.	7.2	1,671
30	Endogenous Estrogens Lower Plasma PCSK9 and LDL Cholesterol But Not Lp(a) or Bile Acid Synthesis in Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 810-814.	1.1	82
31	Circulating Fibroblast Growth Factors as Metabolic Regulatorsâ€"A Critical Appraisal. Cell Metabolism, 2012, 16, 693-705.	7.2	184
32	Stimulation of murine biliary cholesterol secretion by thyroid hormone is dependent on a functional ABCG5/G8 complex. Hepatology, 2012, 56, 1828-1837.	3.6	42
33	1414 GUT MICROBIOTA REGULATES BILE ACID METABOLISM BY REDUCING THE LEVELS OF TAURO-BETAMURICHOLIC ACID, A NATURALLY OCCURRING FXR ANTAGONIST. Journal of Hepatology, 2012, 56, S556.	1.8	3
34	Circulating Human Hepcidin-25 Concentrations Display a Diurnal Rhythm, Increase with Prolonged Fasting, and Are Reduced by Growth Hormone Administration. Clinical Chemistry, 2012, 58, 1225-1232.	1.5	80
35	Inhibition of Intestinal Bile Acid Transporter Slc10a2 Improves Triglyceride Metabolism and Normalizes Elevated Plasma Glucose Levels in Mice. PLoS ONE, 2012, 7, e37787.	1.1	32
36	Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. Journal of Internal Medicine, 2011, 270, 580-588.	2.7	92

#	Article	IF	Citations
37	Lipid lowering with thyroid hormone and thyromimetics. Current Opinion in Lipidology, 2010, 21, 499-506.	1.2	63
38	Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2666-2672.	1.1	147
39	Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia. New England Journal of Medicine, 2010, 362, 906-916.	13.9	275
40	Control of ACAT2 Liver Expression by HNF4Î±. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1235-1241.	1.1	24
41	Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors. Endocrinology, 2009, 150, 1140-1146.	1.4	67
42	Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLEâ€related cardiovascular disease. Scandinavian Journal of Rheumatology, 2009, 38, 184-189.	0.6	23
43	Dramatically Increased Intestinal Absorption of Cholesterol Following Hypophysectomy Is Normalized by Thyroid Hormone. Gastroenterology, 2008, 134, 1127-1136.	0.6	61
44	The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 663-667.	3.3	169
45	The Circulating Metabolic Regulator FGF21 Is Induced by Prolonged Fasting and PPARÎ± Activation in Man. Cell Metabolism, 2008, 8, 169-174.	7.2	441
46	Cholesterol Synthesis Inhibition Elicits an Integrated Molecular Response in Human Livers Including Decreased ACAT2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1200-1206.	1.1	20
47	Age-induced hypercholesterolemia in the rat relates to reduced elimination but not increased intestinal absorption of cholesterol. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E737-E742.	1.8	37
48	Bile acids and lipoprotein metabolism: Effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. Biochemical and Biophysical Research Communications, 2007, 357, 707-711.	1.0	59
49	PPARÎ± is a key regulator of hepatic FGF21. Biochemical and Biophysical Research Communications, 2007, 360, 437-440.	1.0	337
50	Cholesterol regulates ACAT2 gene expression and enzyme activity in human hepatoma cells. Biochemical and Biophysical Research Communications, 2007, 364, 402-409.	1.0	22
51	Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. European Journal of Clinical Investigation, 2006, 36, 98-104.	1.7	111
52	Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. Journal of Internal Medicine, 2006, 260, 530-536.	2.7	355
53	Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10297-10302.	3.3	177
54	Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1057-1064.	1.1	228

#	Article	IF	Citations
55	Telling the liver (not) to make bile acids: a new voice from the gut?. Cell Metabolism, 2005, 2, 209-210.	7.2	3
56	Bile Acid Synthesis in Humans Has a Rapid Diurnal Variation That Is Asynchronous With Cholesterol Synthesis. Gastroenterology, 2005, 129, 1445-1453.	0.6	181
57	ACAT2 Is Localized to Hepatocytes and Is the Major Cholesterol-Esterifying Enzyme in Human Liver. Circulation, 2004, 110, 2017-2023.	1.6	190
58	Growth Hormone Induces Low-Density Lipoprotein Clearance but not Bile Acid Synthesis in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 349-356.	1.1	40
59	Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. Journal of Internal Medicine, 2004, 256, 406-412.	2.7	55
60	Angiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice. Circulation Research, 2004, 94, 1579-1588.	2.0	294
61	Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nature Genetics, 2003, 34, 29-31.	9.4	359
62	Monitoring hepatic cholesterol 7Î±-hydroxylase activity by assay of the stable bile acid intermediate 7Î±-hydroxy-4-cholesten-3-one in peripheral blood. Journal of Lipid Research, 2003, 44, 859-866.	2.0	172
63	Leptin Induces the Hepatic High Density Lipoprotein Receptor Scavenger Receptor B Type I (SR-BI) but Not Cholesterol 7Î±-Hydroxylase (Cyp7a1) in Leptin-deficient (ob/ob) Mice. Journal of Biological Chemistry, 2003, 278, 43224-43228.	1.6	71
64	Differences in the Regulation of the Classical and the Alternative Pathway for Bile Acid Synthesis in Human Liver. Journal of Biological Chemistry, 2002, 277, 26804-26807.	1.6	55
65	Regulation of Hepatic Low-Density Lipoprotein Receptor, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase, and Cholesterol 7Î±-Hydroxylase mRNAs in Human Liver. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4307-4313.	1.8	51
66	Accumulation of Foam Cells in Liver X Receptor-Deficient Mice. Circulation, 2002, 106, 1147-1153.	1.6	165
67	Requirement for Thyroid Hormone Receptor Î² in T3Regulation of Cholesterol Metabolism in Mice. Molecular Endocrinology, 2002, 16, 1767-1777.	3.7	122
68	Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL. Atherosclerosis Supplements, 2002, 3, 23-30.	1.2	33
69	Genetic characterization of Swedish patients with familial hypercholesterolemia: a heterogeneous pattern of mutations in the LDL receptor gene. Atherosclerosis, 2002, 163, 399-407.	0.4	22
70	Analysis of the Ileal Bile Acid Transporter Gene, SLC10A2 , in Subjects With Familial Hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 2039-2045.	1.1	40
71	Growth hormone reduces plasma cholesterol in LDL receptorâ€deficient mice. FASEB Journal, 2001, 15, 1350-1356.	0.2	28
72	Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRÎ²-deficient mice. Journal of Clinical Investigation, 2001, 107, 565-573.	3.9	335

#	Article	IF	Citations
73	LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. European Journal of Clinical Investigation, 2000, 30, 866-870.	1.7	26
74	Biphasic Effects of the Natural Estrogen 17Î²-Estradiol on Hepatic Cholesterol Metabolism in Intact Female Rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1817-1823.	1.1	56
75	Thyroid Hormone Receptor Î²-Deficient Mice Show Complete Loss of the Normal Cholesterol 7Î±-Hydroxylase (CYP7A) Response to Thyroid Hormone but Display Enhanced Resistance to Dietary Cholesterol. Molecular Endocrinology, 2000, 14, 1739-1749.	3.7	105
76	Obesity and Disturbed Lipoprotein Profile in Estrogen Receptor-Î±-Deficient Male Mice. Biochemical and Biophysical Research Communications, 2000, 278, 640-645.	1.0	299
77	Stimulation of Fecal Steroid Excretion After Infusion of Recombinant Proapolipoprotein A-I. Circulation, 1999, 100, 594-598.	1.6	228
78	Endotoxin suppresses mouse hepatic low-density lipoprotein-receptor expression via a pathway independent of the toll-like receptor 4. Hepatology, 1999, 30, 1252-1256.	3.6	14
79	Cholesterol and Lipoprotein Metabolism in Aging. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 832-839.	1.1	79
80	Bile acids and lipoprotein metabolism. Current Opinion in Lipidology, 1999, 10, 269-274.	1.2	23
81	VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor. Journal of Lipid Research, 1999, 40, 913-9.	2.0	22
82	Low frequency of the common Norwegian and Finnish LDLâ€receptor mutations in Swedish patients with familial hypercholesterolaemia. Journal of Internal Medicine, 1998, 243, 19-25.	2.7	10
83	Gemfibrozil-induced decrease in serum ubiquinone and Î±- and Î³-tocopherol levels in men with combined hyperlipidaemia. European Journal of Clinical Investigation, 1998, 28, 235-242.	1.7	27
84	Platelet activity in vivo in hyperlipoproteinemia--importance of combined hyperlipidemia. Thrombosis and Haemostasis, 1998, 79, 268-75.	1.8	8
85	Bovine aortic endothelial cells express a variant of the very low density lipoprotein receptor that lacks the O-linked sugar domain. Journal of Lipid Research, 1998, 39, 2172-81.	2.0	21
86	Lipoprotein Metabolism in the Fat Zucker Rat: Reduced Basal Expression but Normal Regulation of Hepatic Low Density Lipoprotein Receptors*. Endocrinology, 1997, 138, 3276-3282.	1.4	26
87	Therapy for lowering lipoprotein (a) levels. Current Opinion in Lipidology, 1997, 8, 337-341.	1.2	51
88	Adipose Tissue Lipoprotein Lipase and Hormone-Sensitive Lipase. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2287-2292.	1.1	58
89	Importance of Estrogen Receptors in Hepatic LDL Receptor Regulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1800-1805.	1.1	78
90	Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humansâ€"in vitro and in vivo studies. Lipids, 1997, 32, 255-262.	0.7	37

#	Article	IF	Citations
91	The influence of age on low density lipoprotein metabolism: effects of cholestyramine treatment in young and old healthy male subjects. Journal of Internal Medicine, 1997, 242, 329-337.	2.7	24
92	Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study In Stockholm (APSIS). A comparison with healthy controls. Journal of Internal Medicine, 1997, 241, 59-69.	2.7	40
93	Hepatic cholesterol metabolism in human obesity. Hepatology, 1997, 25, 1447-1450.	3.6	88
94	SECRETION AND COMPOSITION OF BILE AFTER HUMAN LIVER TRANSPLANTATION. Transplantation, 1997, 63, 74-80.	0.5	37
95	No Influence of Simvastatin Treatment on Platelet Function In Vivo in Patients With Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 273-278.	1.1	26
96	Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7alpha-hydroxylase in the rat.. Journal of Clinical Investigation, 1997, 99, 2239-2245.	3.9	64
97	Bile acid kinetics and biliary lipid composition in cystic fibrosis. Journal of Hepatology, 1996, 25, 43-48.	1.8	40
98	Endotoxin suppresses rat hepatic low-density lipoprotein receptor expression. Biochemical Journal, 1996, 313, 873-878.	1.7	23
99	Growth hormone potentiates the in vivo biological activities of endotoxin in the rat. European Journal of Clinical Investigation, 1996, 26, 254-258.	1.7	44
100	Gemfibrozil Treatment of Combined Hyperlipoproteinemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 511-516.	1.1	19
101	Regulation of rat hepatic low density lipoprotein receptors. In vivo stimulation by growth hormone is not mediated by insulin-like growth factor I.. Journal of Clinical Investigation, 1996, 97, 292-299.	3.9	59
102	Expression of very low density lipoprotein receptor in the vascular wall. Analysis of human tissues by in situ hybridization and immunohistochemistry. American Journal of Pathology, 1996, 148, 1985-97.	1.9	60
103	Increased prevalence of atherosclerotic wall changes in patients with hyperlipidaemia after renal transplantation. Journal of Internal Medicine, 1996, 239, 177-80.	2.7	12
104	VLDL receptor mediates the uptake of human chylomicron remnants in vitro. Journal of Lipid Research, 1996, 37, 1733-42.	2.0	69
105	Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. Thrombosis and Haemostasis, 1996, 76, 171-6.	1.8	2
106	Metabolism and excretion of ropivacaine in humans. Drug Metabolism and Disposition, 1996, 24, 962-8.	1.7	34
107	Studies on the regulation of hepatic cholesterol metabolism in humans. European Journal of Clinical Investigation, 1995, 25, 215-224.	1.7	31
108	Studies on lipoprotein metabolism in a family with jejunal chylomicron retention. European Journal of Clinical Investigation, 1995, 25, 271-280.	1.7	28

#	Article	IF	Citations
109	Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7Î±-hydroxylase. Hepatology, 1995, 21, 1025-1030.	3.6	62
110	Gemfibrozil Enhances Platelet Activity in Patients With Combined Hyperlipoproteinemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 121-127.	1.1	19
111	Hormonal Regulation of Serum Lipoprotein(a) Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 847-849.	1.1	46
112	Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia.. Journal of Clinical Investigation, 1995, 95, 2161-2169.	3.9	100
113	Effects of Ursodeoxycholic Acid on Plasma Lipids. Scandinavian Journal of Gastroenterology, 1994, 29, 24-26.	0.6	4
114	Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism.. Gut, 1994, 35, 1116-1120.	6.1	34
115	Lack of association between apolipoprotein E allele É›4 and sporadic Alzheimer's disease. Neuroscience Letters, 1994, 169, 175-178.	1.0	56
116	Effects of selective LDLâ€apheresis and pravastatin therapy on platelet function in familial hypercholesterolaemia. European Journal of Clinical Investigation, 1994, 24, 488-496.	1.7	35
117	Growth hormone and hepatic lipoprotein metabolism. Current Opinion in Lipidology, 1994, 5, 160-165.	1.2	100
118	Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clinical Nephrology, 1994, 41, 183-90.	0.4	94
119	Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy. Journal of Internal Medicine, 1993, 233, 173-178.	2.7	49
120	Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. American Journal of Medicine, 1993, 94, 13-20.	0.6	169
121	Serum 7 alpha-hydroxy-4-cholesten-3-one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test.. Gut, 1993, 34, 698-701.	6.1	58
122	Adipocyte beta-adrenoceptor sensitivity influences plasma lipid levels.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 967-972.	3.8	23
123	Loss of resistance to dietary cholesterol in the rat after hypophysectomy: importance of the presence of growth hormone for hepatic low density lipoprotein-receptor expression.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 8851-8855.	3.3	51
124	Apolipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentrations. Clinical Chemistry, 1993, 39, 2125-2129.	1.5	138
125	Stimulation of rat hepatic low density lipoprotein receptors by glucagon. Evidence of a novel regulatory mechanism in vivo.. Journal of Clinical Investigation, 1993, 91, 2796-2805.	3.9	62
126	Growth hormone and low-density lipoproteins. Acta Endocrinologica, 1993, 128 Suppl 2, 26-8.	0.0	2

#	Article	IF	Citations
127	Apolipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentrations. Clinical Chemistry, 1993, 39, 2125-9.	1.5	49
128	Importance of growth hormone for the induction of hepatic low density lipoprotein receptors.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 6983-6987.	3.3	233
129	Digoxin-interactions in man: Spironolactone reduces renal but not biliary digoxin clearance. European Journal of Clinical Pharmacology, 1992, 42, 481-485.	0.8	26
130	Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma.. Journal of Clinical Investigation, 1992, 89, 1166-1171.	3.9	142
131	Effects of growth hormone on low-density lipoprotein metabolism. Acta Paediatrica, International Journal of Paediatrics, Supplement, 1992, 383, 67-8; discussion 69.	1.0	0
132	Molecular aspects of human lipid metabolism. European Journal of Clinical Nutrition, 1992, 46, 153-60.	1.3	0
133	Influence of age on the metabolism of plasma low density lipoproteins in healthy males.. Journal of Clinical Investigation, 1991, 87, 591-596.	3.9	134
134	Age-related changes in the metabolism of cholesterol in rat liver microsomes. Lipids, 1991, 26, 349-352.	0.7	30
135	Digoxin-verapamil interaction: Reduction of biliary but not renal digoxin clearance in humans. Clinical Pharmacology and Therapeutics, 1991, 49, 256-262.	2.3	73
136	Bile acid sequestrants: Mechanisms of action on bile acid and cholesterol metabolism. European Journal of Clinical Pharmacology, 1991, 40, S53-S58.	0.8	36
137	Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. European Journal of Clinical Pharmacology, 1991, 40, S53-S58.	0.8	117
138	Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test.. Gut, 1991, 32, 1044-1048.	6.1	38
139	Regulation of Hepatic Cholesterol Metabolism in Man. Annals of Medicine, 1991, 23, 177-180.	1.5	13
140	Metabolism of lipoprotein remnants in humans. Studies during intestinal infusion of fat and cholesterol in subjects with varying expression of the low density lipoprotein receptor.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991, 11, 827-837.	3.8	36
141	Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. Journal of Lipid Research, 1991, 32, 935-40.	2.0	52
142	Distribution of cholesterol between vesicles and micelles in human gallbladder bile: influence of treatment with chenodeoxycholic acid and ursodeoxycholic acid. Hepatology, 1991, 13, 104-10.	3.6	6
143	Hepatic cholesterol metabolism in cholesterol gallstone disease. Journal of Lipid Research, 1991, 32, 469-75.	2.0	45
144	Low density lipoprotein receptor-binding activity in human tissues: quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 3469-3473.	3.3	97

#	Article	IF	Citations
145	Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2598-2602.	3.3	118
146	Interactions in the renal and biliary elimination of digoxin: Stereoselective difference between quinine and quinidine. Clinical Pharmacology and Therapeutics, 1990, 47, 20-26.	2.3	77
147	Increased turnover of very low density lipoprotein triglyceride during treatment with cholestyramine in familial hypercholesterolaemia. Journal of Internal Medicine, 1990, 227, 201-206.	2.7	28
148	Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. Journal of Internal Medicine, 1990, 228, 241-247.	2.7	47
149	Characteristics of biliary lipid metabolism after liver transplantation. Hepatology, 1990, 12, 1222-1228.	3.6	53
150	Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet, The, 1990, 335, 1360-1363.	6.3	197
151	Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of Cholesterol. New England Journal of Medicine, 1990, 323, 224-228.	13.9	267
152	Platelet aggregability in humans: contrasting in vivo and in vitro findings during sympathoâ€adrenal activation and relationship to serum lipids. European Journal of Clinical Investigation, 1990, 20, 398-405.	1.7	30
153	Influence of Metoprolol Treatment on Sympatho-Adrenal Activation of Fibrinolysis. Thrombosis and Haemostasis, 1990, 63, 482-487.	1.8	41
154	Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients. Journal of Lipid Research, 1990, 31, 2219-26.	2.0	66
155	Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thrombosis and Haemostasis, 1990, 63, 482-7.	1.8	15
156	Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Research, 1990, 50, 483-7.	0.4	61
157	Oestrogen-induced changes in lipoprotein metabolism: role in prevention of atherosclerosis in the cholesterol-fed rabbit. European Journal of Clinical Investigation, 1989, 19, 395-403.	1.7	43
158	Early determination of serum lipids and apolipoproteins in acute myocardial infarction: possibility for immediate intervention. Journal of Internal Medicine, 1989, 226, 297-301.	2.7	36
159	Effects of estrogen on low density lipoprotein metabolism in males. Short-term and long-term studies during hormonal treatment of prostatic carcinoma.. Journal of Clinical Investigation, 1989, 84, 802-810.	3.9	90
160	Estrogen-induced gallstone formation in males. Relation to changes in serum and biliary lipids during hormonal treatment of prostatic carcinoma.. Journal of Clinical Investigation, 1989, 84, 811-816.	3.9	96
161	Studies on acyl-coenzyme A: cholesterol acyltransferase activity in human liver microsomes. Journal of Lipid Research, 1989, 30, 739-46.	2.0	47
162	Effects of treatment with clofibrate, bezafibrate, and ciprofibrate on the metabolism of cholesterol in rat liver microsomes. Journal of Lipid Research, 1989, 30, 953-8.	2.0	45

#	Article	IF	Citations
163	Effect of thiazide treatment on biliary lipid composition in healthy volunteers. European Journal of Clinical Pharmacology, 1989, 37, 95-96.	0.8	11
164	Interindividual variability in biliary excretion of ceftriaxone: effects on biliary lipid metabolism and on intestinal microflora. European Journal of Clinical Investigation, 1988, 18, 261-266.	1.7	35
165	Sn-protoporphyrin lowers serum bilirubin levels, decreases biliary bilirubin output, enhances biliary heme excretion and potently inhibits hepatic heme oxygenase activity in normal human subjects. Hepatology, 1988, 8, 625-631.	3.6	45
166	Bile acid metabolism in heterozygous familial hypercholesterolaemia: a study comparing affected and unaffected siblings of four kindreds. European Journal of Clinical Investigation, 1988, 18, 153-161.	1.7	8
167	Plasma cholesterol esterification rate in hyperlipoproteinaemia: Relation to cholesterol elimination. Scandinavian Journal of Clinical and Laboratory Investigation, 1988, 48, 481-487.	0.6	2
168	Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in mouse peritoneal macrophages. Biochemical Journal, 1988, 255, 529-34.	1.7	4
169	Regulation of biliary cholesterol secretion in man. Agents and Actions Supplements, 1988, 26, 83-97.	0.2	0
170	Assay of unesterified cholesterol-5,6-epoxide in human serum by isotope dilution mass spectrometry. Levels in the healthy state and in hyperlipoproteinemia. Journal of Lipid Research, 1988, 29, 1031-8.	2.0	27
171	Bile acid metabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 5434-5438.	3.3	102
172	Quinidine reduces biliary clearance of digoxin in man. European Journal of Clinical Investigation, 1987, 17, 262-265.	1.7	63
173	Plasma Exchange in a Patient with Heterozygous Familial Hypercholesterolaemia Resistant to Drug Therapy. Acta Medica Scandinavica, 1987, 221, 317-320.	0.0	6
174	Spontaneous Regression of Buddâ€Chiari Syndrome (Hepatic Venous Occlusion) in a Young Female. Acta Medica Scandinavica, 1987, 221, 503-507.	0.0	3
175	Studies on Human Macrophage Lipoprotein Uptake: Relation to Atherosclerosis. Acta Medica Scandinavica, 1987, 221, 45-49.	0.0	1
176	On the possible use of the serum level of 7 alpha-hydroxycholesterol as a marker for increased activity of the cholesterol 7 alpha-hydroxylase in humans. Journal of Lipid Research, 1987, 28, 889-94.	2.0	85
177	Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. Journal of Lipid Research, 1987, 28, 1137-43.	2.0	181
178	Ursodeoxycholic acid treatment in humans: effects on plasma and biliary lipid metabolism with special reference to very low density lipoprotein triglyceride and bile acid kinetics. European Journal of Clinical Investigation, 1986, 16, 169-177.	1.7	23
179	Bile acid synthesis in man: assay of hepatic microsomal cholesterol 7 alpha-hydroxylase activity by isotope dilution-mass spectrometry. Journal of Lipid Research, 1986, 27, 82-8.	2.0	70
180	The diagnostic value of fasting individual serum bile acids in anicteric alcoholic liver disease: Relation to liver morphology. Hepatology, 1985, 5, 108-111.	3.6	11

#	Article	IF	Citations
181	Portal venous bile acids in cholesterol gallstone disease: Effect of treatment with chenodeoxycholic and cholic acids. Hepatology, 1985, 5, 661-665.	3.6	7
182	Influence of Age on Secretion of Cholesterol and Synthesis of Bile Acids by the Liver. New England Journal of Medicine, 1985, 313, 277-282.	13.9	242
183	Serum Concentrations of Ursodeoxycholic Acid in Portal Venous and Systemic Venous Blood of Fasting Humans as Determined by Isotope Dilutionâ€"Mass Spectrometry. Gastroenterology, 1985, 88, 126-133.	0.6	32
184	Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia. European Journal of Clinical Investigation, 1984, 14, 73-78.	1.7	27
185	Triglyceride metabolism in human liver: studies on hepatic phosphatidic-acid phosphatase in obese and non-obese subjects. European Journal of Clinical Investigation, 1984, 14, 233-237.	1.7	8
186	3-hydroxy-3-methylglutaryl coenzyme A reductase in human liver microsomes: active and inactive forms and cross-reactivity with antibody against rat liver enzyme. Journal of Lipid Research, 1984, 25, 1159-66.	2.0	38
187	Type III hyperlipoproteinemia: recent insights into the genetic defect of familial dysbetalipoproteinemia. Advances in Internal Medicine, 1984, 29, 385-411.	0.9	72
188	Bile acid metabolism in hypothyroid subjects: response to substitution therapy. European Journal of Clinical Investigation, 1983, 13, 99-106.	1.7	27
189	Regulation of Hepatic Lipoprotein Receptors in the Dog. RAPID REGULATION OF APOLIPOPROTEIN B,E RECEPTORS, BUT NOT OF APOLIPOPROTEIN E RECEPTORS, BY INTESTINAL LIPOPROTEINS AND BILE ACIDS. Journal of Clinical Investigation, 1983, 71, 816-831.	3.9	117
190	Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels. Journal of Lipid Research, 1983, 24, 461-8.	2.0	48
191	Ceftriaxone: renal and biliary excretion and effect on the colon microflora. Journal of Antimicrobial Chemotherapy, 1982, 10, 207-215.	1.3	138
192	Hepatic Uptake of Bile Acids in Man. Journal of Clinical Investigation, 1982, 70, 724-731.	3.9	201
193	Hepatic cholesterol metabolism in obesity: activity of microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase. Journal of Lipid Research, 1982, 23, 770-3.	2.0	36
194	Influence of bile acids on the soluble phosphatidic acid phosphatase in rat liver. Biochemical and Biophysical Research Communications, 1981, 100, 606-612.	1.0	23
195	Clofibrate treatment and bile cholesterol saturation: short-term and long-term effects and influence of combination with chenodeoxycholic acid. European Journal of Clinical Investigation, 1981, 11, 185-189.	1.7	24
196	Effects of feeding chenodeoxycholic acid on metabolism of cholesterol and bile acids in germ-free rats. Lipids, 1981, 16, 228-233.	0.7	16
197	Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment. Journal of Lipid Research, 1981, 22, 410-22.	2.0	80
198	Metabolism of endogenous plasma triglyceride in familial hypercholesterolaemia: studies of affected and unaffected siblings of two kindreds. European Journal of Clinical Investigation, 1980, 10, 23-26.	1.7	2

#	Article	IF	Citations
199	Metabolism of endogenous plasma triglyceride in familial hypercholesterolaemia: studies of affected and unaffected siblings of two kindreds. European Journal of Clinical Investigation, 1980, 10, 23-26.	1.7	7
200	Effects of cholic acid on the metabolism of endogenous plasma triglyceride and on biliary lipid composition in hyperlipoproteinemia. Journal of Lipid Research, 1980, 21, 1-9.	2.0	21
201	Biliary lipid composition during treatment with different hypolipidaemic drugs. European Journal of Clinical Investigation, 1979, 9, 185-190.	1.7	101
202	Prevalence of gallbladder disease in hyperlipoproteinemia. Digestive Diseases and Sciences, 1979, 24, 459-464.	1.1	48
203	Hepatic cholesterol metabolism in normo- and hyperlipidemic patients with cholesterol gallstones. Journal of Lipid Research, 1979, 20, 107-15.	2.0	36
204	Effect of Chenodeoxycholic Acid on Serum and Biliary Lipids in Patients with Hyperlipoproteinaemia. Clinical Science and Molecular Medicine, 1978, 54, 451-455.	0.8	22
205	Lecithin: Cholesterol Acyl Transfer Rate in Plasma and its Relations to Lipoprotein Concentrations and to Kinetics of Bile Acids and Triglycerides in Hyperlipoproteinemic Subjects. Scandinavian Journal of Clinical and Laboratory Investigation, 1978, 38, 103-110.	0.6	9
206	Hypocalcaemia with Zonular Cataract Due to Idiopathic Hypoparathyroidism. Acta Medica Scandinavica, 1978, 203, 223-226.	0.0	17
207	Individual serum bile acid concentrations in normo- and hyperlipoproteinemia as determined by mass fragmentography: relation to bile acid pool size.. Journal of Lipid Research, 1978, 19, 527-537.	2.0	54
208	Individual serum bile acid concentrations in normo- and hyperlipoproteinemia as determined by mass fragmentography: relation to bile acid pool size. Journal of Lipid Research, 1978, 19, 527-37.	2.0	52
209	Bile acid kinetics in relation to endogenous tryglyceride metabolism in various types of hyperlipoproteinemia. Journal of Lipid Research, 1978, 19, 1004-16.	2.0	73
210	Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. Journal of Lipid Research, 1978, 19, 1017-24.	2.0	131
211	Influence of cholestyramine on synthesis of cholesterol and bile acids in germfree rats. Journal of Lipid Research, 1978, 19, 972-7.	2.0	18
212	Postprandial serum bile acids in healthy man. Evidence for differences in absorptive pattern between individual bile acids.. Gut, 1977, 18, 606-609.	6.1	92
213	Influence of Deoxycholic Acid on Biliary Lipids in Man. Clinical Science and Molecular Medicine, 1977, 53, 249-256.	0.8	57
214	Individual Bile Acids in Portal Venous and Systemic Blood Serum of Fasting Man. Gastroenterology, 1977, 73, 1377-1382.	0.6	115
215	Effects of cholesterol feeding on synthesis and metabolism of cholesterol and bile acids in germfree rats. Journal of Lipid Research, 1977, 18, 717-21.	2.0	25
216	Elimination of Cholesterol in Hyperlipoproteinaemia. Clinical Science and Molecular Medicine, 1976, 51, 393-397.	0.8	33

#	Article	IF	Citations
217	Evidence for the absorption of bile acids in the proximal small intestine of normo- and hyperlipidaemic subjects.. Gut, 1976, 17, 420-425.	6.1	78
218	Novel Effects of Histamine on Lipoprotein Metabolism: Suppression of Hepatic Low Density Lipoprotein Receptor Expression and Reduction of Plasma High Density Lipoprotein Cholesterol in the Rat. , 0, .		4
219	Lipoprotein Metabolism in the Fat Zucker Rat: Reduced Basal Expression but Normal Regulation of Hepatic Low Density Lipoprotein Receptors. , 0, .		6
220	Nutrition and stem cell integrity in aging. Journal of Internal Medicine, 0, , .	2.7	2